Champions Oncology, Inc.
CSBR
$7.63
$0.222.97%
NASDAQ
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -11.76% | 41.77% | 16.56% | 11.94% | 7.12% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -11.76% | 41.77% | 16.56% | 11.94% | 7.12% |
| Cost of Revenue | 0.29% | -15.70% | 12.24% | -7.96% | -1.20% |
| Gross Profit | -24.70% | 149.93% | 22.32% | 43.31% | 17.77% |
| SG&A Expenses | 6.54% | -7.83% | -17.18% | -9.28% | -1.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.67% | -14.09% | -5.70% | -15.75% | -6.41% |
| Operating Income | -1,145.12% | 274.58% | 137.44% | 152.08% | 109.57% |
| Income Before Tax | -933.68% | 279.36% | 135.87% | 152.56% | 92.52% |
| Income Tax Expenses | -59.26% | 109.09% | 0.00% | -25.00% | -505.00% |
| Earnings from Continuing Operations | -1,583.49% | 277.67% | 135.15% | 151.17% | 95.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,583.49% | 277.67% | 135.15% | 151.17% | 95.74% |
| EBIT | -1,145.12% | 274.58% | 137.44% | 152.08% | 109.57% |
| EBITDA | -312.56% | 333.64% | 176.89% | 184.39% | 148.14% |
| EPS Basic | -1,567.50% | 276.30% | 134.94% | 150.84% | 95.76% |
| Normalized Basic EPS | -771.68% | 277.98% | 135.64% | 152.21% | 114.14% |
| EPS Diluted | -1,195.15% | 263.16% | 132.59% | 147.37% | 94.69% |
| Normalized Diluted EPS | -771.68% | 269.78% | 134.59% | 150.60% | 114.14% |
| Average Basic Shares Outstanding | 1.18% | 0.79% | 0.72% | 0.64% | 0.27% |
| Average Diluted Shares Outstanding | 1.18% | 5.67% | 3.85% | 3.97% | 0.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |